Amgen, Novartis Trade Rights For Migraine, Alzheimer's Drugs
This article was originally published in Scrip
Amgen traded certain ex-US rights to its Phase III calcitonin gene-related peptide (CGRP) inhibitor for migraine headaches to acquire shared global rights to Novartis's early-stage candidate for Alzheimer's disease, raising an important question: Who is getting the better deal?
You may also be interested in...
An interim look at two Phase II/III trials showed the drug worsened cognition in people at high risk of developing Alzheimer's disease. This is the 16th failure of a BACE-targeting therapy.
Amgen started 2018 off on solid footing with a 2% jump in Q1 revenue to $5.55bn versus consensus estimates of $5.4bn, but new drugs like the CGRP inhibitor Aimovig are needed to keep the momentum going and supplement declining sales for key products.
A new trial for CNP520 will see if the Amgen/Novartis BACE1 inhibitor can prevent, stop or slow Alzheimer's disease progression in pre-symptomatic patients, but recruiting enough patients with the APOE4 gene will require a massive screening effort.